DXB has $17m in cash.
DXB has 40c options built into the interim analysis readout.
DXB has >$200m of potential milestone payments, i'd say a portion would be paid to DXB in March upon positive interim analysis as the first milestone. That could range anywhere between $20-30m (I'm speculating the amount)
Also, the high start up costs of the trial have already been paid at the beginning.
Unless the trial falls flat on it's face then cash is not an issue. I wouldn't worry about funding.
Ann: ACTION3 IND Approved in China, page-190
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.030(8.00%) |
Mkt cap ! $225.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.5¢ | 37.0¢ | $637.2K | 1.624M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16500 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 169113 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |